
LISTING OF THE CLAIMS:

- 1. (Original) A method for evaluating a physical state of a subject, which method comprises comparing (i) an expression profile of surrogate cells from the subject with (ii) a normal expression profile of surrogate cells from a normal subject or subjects, wherein a difference between the expression profiles is indicative of the physical state of the subject under investigation.
- 2. (Original) A method for evaluating a disease or disorder of a subject, which method comprises comparing (i) an expression profile of surrogate cells from the subject with (ii) a normal expression profile of surrogate cells from a normal subject or subjects, wherein a difference between the expression profiles is indicative of the disease or disorder of the subject under investigation.
 - 3. (Cancelled)
 - 4. (Cancelled)
 - 5. (Cancelled)
 - 6. (Original) The method according to claim 2, wherein the subject is a human.
- 7. (Original) The method according to claim 2, wherein the surrogate cells are peripheral blood leukocytes.
- 8. (Original) The method according to claim 7 wherein the peripheral blood leukocytes are selected from the group consisting of monocytes, macrophages, lymphocytes, granulocytes, neutrophils, basophils, and eosinophils, or other white blood cell types or subtypes.
- 9. (Original) The method according to claim 2, wherein the disease is the presence of a cancer in the subject.
- 10. (Currently Amended) The method according to claim 9, wherein the cancer is prostate cancer or breast cancer.

- 11. (Cancelled)
- 12. (Original) The method according to claim 2, wherein the disease is the presence of a neurological disorder.
- 13. (Currently Amended) The method according to claim 12, wherein the neurological disorder is a neurodegenerative disease or Alzheimer's disease.
 - 14. (Cancelled)
- 15. (Original) The method according to claim 2, wherein the disorder is a psychiatric disorder or a mood disorder.
- 16. (Currently Amended) The method according to claim 15, wherein the disorder is selected from the group consisting of schizophrenia, bipolar disorder and major depression.
 - 17. (Cancelled)
 - 18. (Cancelled)
 - 19. (Cancelled)
 - 20. (Cancelled)
 - 21. (Cancelled)
 - 22. (Cancelled)
 - 23. (Cancelled)
 - 24. (Cancelled)
- 25. (Currently Amended) The method according to claim 2, wherein evaluating the disease or disorder is selected from the group consisting of comprises classifying the disease or disorder, diagnosing the presence of a disease or disorder, determining the prognosis of the subject,


monitoring a therapy, selecting a therapy, and assessment of susceptibility for the disease or disorder.



- 42. (Original) The method according to claim 2, which comprises obtaining an expression profile with reverse transcriptase-polymerase chain reaction (RT-PCR).
- 43. (Original) A method for evaluating a physical state of a subject, which method comprises comparing an expression profile of surrogate cells from the subject with an expression profile of surrogate cells from a known subject or subjects determined to have the physical state, wherein a similarity in the expression profiles indicates that the subject has the same physical state as the known subject.
- 44. (Original) A method for monitoring a physical state of a subject, which method comprises comparing an expression profile of surrogate cells from the subject with an expression profile of surrogate cells from a known subject or subjects determined to have the physical state and have a known degree of that physical state, wherein a similarity in the expression profiles indicates that the subject has a similar degree of that physical state as the known subject.
- 45. (Original) A method for evaluating a treatment or therapy in a subject, which method comprises comparing an expression profile of surrogate cells from the subject after the treatment or therapy with an expression profile of surrogate cells from the subject prior to treatment or therapy, wherein a difference in the expression profiles indicates an effect of the treatment or therapy on the subject.
- 46. (Currently Amended) The method according to claim 45, whereby the treatment is exposure to a candidate theraputic therapeutic compound.
- 47. (Original) A method for evaluating a treatment or therapy in a subject, which method comprises comparing the expression profile of the subject after exposing the subject to the treatment or therapy with a normal expression profile of surrogate cells from a normal subject or subjects, wherein a similarity of the expression profiles is indicative of a therapeutic benefit of the treatment or therapy on the subject.
- 48. (Currently Amended) The method according to claim 47, whereby the treatment is exposure to a candidate theraputic therapeutic compound.

- 49. (Original) A method for evaluating a treatment or therapy in a subject, which method comprises comparing the expression profile of the subject after exposing the subject to the treatment or therapy with an expression profile of surrogate cells from other subjects with the same physical state prior to exposure to different therapies, wherein a similarity of the expression profiles is indicative of low treatment or therapy benefit on the subject.
- 50. (Currently Amended) The method according to claim 49, whereby the treatment is exposure to a candidate theraputic therapeutic compound.
 - 51. (Cancelled)
 - 52. (Cancelled)
 - 53. (Cancelled)
 - 54. (Cancelled)
- 55. (Currently Amended) A method for predicting a response to treatement treatment or therapy in a subject, which method comprises comparing an expression profile of nucleic acids from surrogate cells from the subject prior to exposing the subject to a treatment or therapy, with an expression profile of nucleic acids from surrogate cells from other subjects with the same physical state prior to exposure to different therapies, wherein a similarity in the expression profiles predicts an effect of the treatment or therapy on the subject based on the effect of that therapy on another subject or subjects having a similar expression profile.
- 56. (Original) A method for choice of treatment or therapy for a subject, which method comprises comparing an expression profile of nucleic acids from surrogate cells from the subject prior to exposing the subject to a treatment or therapy with an expression profile of nucleic acids from surrogate cells from other subjects with the same physical state prior to exposure to different treatment or therapies, wherein a similarity in the expression profiles predicts an effect of the treatment or therapy on the subject based on the effect of that therapy on another subjects having a similar expression profile.

- 57. (Cancelled)
- 58. (Cancelled)
- 59. (Cancelled)
- 60. (Cancelled)
- 61. (Cancelled)
- 62. (Cancelled)
- 63. (Cancelled)
- 64. (Original) A method for identifying a nucleic acid containing a sequence alteration that results in and/or contributes to a disease or disorder, and/or results in and/or contributes to susceptibility for a disease or disorder, which method comprises (a) selecting a nucleic acid that has altered expression in a surrogate cell from a subject with the disease or disorder, when compared to a surrogate cell from a normal subject or subjects; and (b) comparing the sequence of the nucleic acid, including the entire transcribed region, plus upstream and downstream controlling elements, from the subject with disease or disorder and the normal subject or subjects, wherein a sequence difference indicates that the nucleic acid sequence results in and/or contributes to a disease or disorder, and/or results in or contributes to susceptibility for a disease or disorder.
- 65. (Original) The method of claim 64, wherein the nucleic acid is adjacent to, near to, or within, a region of genetic linkage to the physical state.
 - 66. (Cancelled)
 - 67. (Cancelled)
 - 68. (Cancelled)
 - 69. (Cancelled)



- 86. (Original) A method for determining the prognosis of a subject having a disease or disorder by the detection of a nucleic acid alteration in said subject, wherein the nucleic acid alteration is identified using the method of claim 64.
 - 87. (Cancelled)
- 88. (Original) A method for determining the susceptibility of a subject for developing a disease or disorder by the detection of a nucleic acid alteration in said subject, wherein the nucleic acid alteration is identified using the method of claim 64.
 - 89. (Cancelled)
- 90. (Original) A method for developing therapeutic compounds to be administered to a subject with a disease or disorder resulting from and/or contributed to, by a nucleic acid sequence alteration identified by the method of claim 64, whereby the therapeutic compounds are designed to normalize the function or expression of the altered nucleic sequence.
 - 91. (Cancelled)
 - 92. (Cancelled)
- 93. (Original) A method for treating a patient suffering from a disease or a disorder resulting from and/or contributed to, by a nucleic acid sequence alteration that had been previously identified using the method of claim 64, comprising administering to a patient in need of such treatment therapeutically effective amounts of a normal counterpart of the nucleic acid sequence.
 - 94. (Cancelled)
 - 95. (Cancelled)
 - 96. (Cancelled)
- 97. (Currently Amended) A method for treating a subject with a disease or disorder resulting from and/or contributed to, by an alterated altered expression level of a nucleic acid

identified to have altered expression using the method of claim 2, comprising administering to a subject in need of such treatment therapeutically effective amounts of the nucleic acid or therapeutically effective amounts of inhibitory nucleic acid sequence specific for the nucleic acid.

- 98. (Cancelled)
- 99. (Cancelled)
- 100. (Cancelled)
- 101. (Cancelled)
- 102. (Cancelled)
- 103. (Cancelled)
- 104. (Currently Amended) A method for developing therapeutic compounds for a disease or disorder resulting from and/or contributed to, by an alterated altered expression level of a nucleic acid identified to have altered expression using the method of claim 2, whereby the therapy is designed to normalize the function or expression of the nucleic sequence.